Latest Releases

Jan 06, 2025

Candid Therapeutics Enters into Agreement with WuXi Biologics on Trispecific T-cell Engager

Read More »

Dec 16, 2024

Candid Therapeutics and EpimAb Biotherapeutics Enter Into Research Collaboration to Discover and Develop Novel T-Cell Engagers for Autoimmune Indications

Read More »

Dec 16, 2024

Candid Therapeutics and Ab Studio Enter Into Research Collaboration to Discover and Develop Novel T Cell Engagers for Autoimmune Indications

Read More »

Dec 16, 2024

Nona Biosciences Announces Discovery Collaboration with Candid Therapeutics for Next-Generation T-Cell Engagers

Read More »

Oct 16, 2024

Candid Therapeutics Appoints Highly Accomplished Industry Leaders Angie You, Ph.D. and Dan Puckett to it’s Board of Directors

Read More »

Sep 09, 2024

Candid Therapeutics Debuts with $370M Capital Raise to Clinically Evaluate Potentially Transformative Autoimmune Therapies

Read More »